MAPT and Alzheimer disease: Importantly, we found that the CSF α-synuclein levels might correlate with AD severity and progression, which was consistent with a recent study indicating that increased α-synuclein displayed a stronger association with cognitive impairment than soluble Aβ and tau levels [40].